Clinical Trials Logo

Vertebral Compression Fractures clinical trials

View clinical trials related to Vertebral Compression Fractures.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02657265 Completed - Trauma Clinical Trials

SpineJack® Versus Conservative Treatment Study (SPICO Study)

Start date: January 13, 2016
Phase: N/A
Study type: Interventional

This study will compare two standard treatments in acute stable traumatic vertebral fractures (types A1 and A3.1 by Magerl Classification). The two treatments are as follows: 1. SpineJack® system 2. Conservative Orthopedic Management consisting of brace and pain medication.

NCT ID: NCT02608801 Completed - Hip Fractures Clinical Trials

Prediction and Secondary Prevention of Fractures

NOFRACTsub
Start date: April 2015
Phase:
Study type: Observational

The purpose of this study is to investigate patient related factors that contribute to increased risk of recurrent fractures and to investigate patient adherence to prescribed anti-osteoporotic drugs.

NCT ID: NCT02461810 Completed - Osteoporosis Clinical Trials

Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques

SAKOS
Start date: April 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the safety and effectiveness of the SpineJack® with the Kyphx Xpander® Inflatable Bone Tamp and support a non-inferiority finding for the use of SpineJack® VCF treatment system versus Balloon Kyphoplasty.

NCT ID: NCT01482793 Completed - Clinical trials for Vertebral Compression Fractures

A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures

Start date: November 2011
Phase: N/A
Study type: Interventional

The objective of this study is to gather data regarding the efficacy, safety and cost-effectiveness of percutaneous vertebroplasty in the acute fracture group with fractures less than 6 weeks old. The AVAMAX vertebroplasty kits (Care Fusion) will be used for all vertebroplasties. The primary effectiveness analysis will be based on the number of patients whose numeric rating pain score drops from above 7 out of 10 at baseline to below 4 out of 10 at two weeks post-intervention. Our hypothesis is that the vertebroplasty group will have a significantly larger proportion of patients achieving pain reduction than the control group. A secondary analysis will compare the change in mean pain scores and specific activity related pain scores between the two groups at 3 days, 14 days and at 1, 3 and 6 months. Another secondary effectiveness analysis will include the mean change in the back-pain specific limitation in function as quantified by the Roland Scale at these same data collection time points.